Drug Price Trends for NDC 70700-0156

Average Pharmacy Cost for 70700-0156

Drug Name	NDC	Price/Unit ($)	Unit	Date
ENILLORING VAGINAL RING	70700-0156-91	50.04303	EACH	2026-03-18
ENILLORING VAGINAL RING	70700-0156-11	50.04303	EACH	2026-03-18
ENILLORING VAGINAL RING	70700-0156-91	50.51333	EACH	2026-02-18

Best Wholesale Price for NDC 70700-0156

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ENILLORING	AvKare, LLC	70700-0156-91	3	135.67	45.22333	2023-10-11 - 2028-06-14	FSS

Analysis of Diclofenac Sodium Gel NDC 70700-0156: Market Dynamics and Pricing Projections

Last updated: February 18, 2026

Diclofenac sodium gel, identified by National Drug Code (NDC) 70700-0156, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. This analysis examines current market conditions and projects future pricing trends for this specific product.

What is the Current Market Landscape for Diclofenac Sodium Gel NDC 70700-0156?

The market for topical NSAIDs, including diclofenac sodium gel, is characterized by established therapeutic use, generic competition, and a growing demand for localized pain relief. NDC 70700-0156 represents a specific formulation and packaging of diclofenac sodium gel.

Key Market Participants and Product Offerings:

• Manufacturers: Multiple pharmaceutical companies manufacture generic diclofenac sodium gel. The specific manufacturer of NDC 70700-0156 is crucial for understanding its supply chain and competitive positioning. Without explicit manufacturer identification for this NDC, analysis relies on the broader generic diclofenac sodium gel market.
• Dosage Forms: Diclofenac sodium is available in various topical formulations, including gels, patches, and creams. NDC 70700-0156 is specifically a gel.
• Therapeutic Indications: The primary indications are osteoarthritis, acute strains, sprains, and other soft tissue injuries, providing localized pain and inflammation relief with reduced systemic absorption compared to oral NSAIDs.
• Competition: The market is highly competitive due to the availability of numerous generic versions. Major competitors includeVoltaren Gel (original branded product, now largely genericized), and other generic manufacturers.

Market Size and Growth Drivers:

• The global topical NSAIDs market is projected to grow at a compound annual growth rate (CAGR) of approximately 5% to 7% over the next five years, driven by an aging population, increasing prevalence of musculoskeletal disorders, and a preference for localized treatments with fewer gastrointestinal side effects than oral NSAIDs.
• The accessibility of generic diclofenac sodium gel contributes to its widespread use in both prescription and over-the-counter (OTC) markets. The specific market penetration of NDC 70700-0156 depends on its distribution channels and formulary placement.

Regulatory Environment:

• Diclofenac sodium gel is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA). Generic drug approval requires demonstrating bioequivalence to the reference listed drug.
• The FDA's Orange Book lists approved drug products with therapeutic equivalents. Generic products are categorized based on their bioequivalence and therapeutic potential.

What are the Pricing Determinants for Diclofenac Sodium Gel NDC 70700-0156?

Pricing for generic pharmaceuticals like diclofenac sodium gel is influenced by several factors, including manufacturing costs, market competition, supply chain dynamics, and reimbursement policies.

Cost of Goods Sold (COGS):

• Raw Material Costs: The price of diclofenac sodium active pharmaceutical ingredient (API) and excipients (e.g., carbomer, propylene glycol, preservatives) directly impacts manufacturing costs. Fluctuations in global API supply chains can affect these prices.
• Manufacturing Overhead: Labor, energy, facility maintenance, and quality control processes contribute to overall production costs. Economies of scale are significant for high-volume generic manufacturers.
• Packaging and Labeling: Costs associated with tubes, cartons, and labeling vary based on material choices and regulatory requirements.

Market Competition and Supply:

• Number of Generic Competitors: A higher number of manufacturers producing equivalent products generally leads to lower prices due to increased supply and price competition.
• Market Share of NDC 70700-0156: The volume of sales for this specific NDC affects its pricing power. High sales volume can sometimes lead to volume discounts for distributors.
• Manufacturer's Pricing Strategy: Manufacturers may adopt aggressive pricing strategies to gain market share, particularly for new generic entrants.

Distribution Channels and Markups:

• Wholesalers and Distributors: Each entity in the distribution chain adds a markup, contributing to the final price paid by pharmacies or healthcare providers.
• Pharmacy Markups: Retail pharmacies apply their own markups to prescription drugs.

Reimbursement and Payer Policies:

• Pharmacy Benefit Managers (PBMs) and Insurance Companies: PBMs negotiate drug prices with manufacturers and pharmacies. Their formularies and preferred drug lists influence which products are covered and at what cost-sharing level for patients.
• Medicare and Medicaid Reimbursement: Government programs have specific reimbursement rates and pricing guidelines that can influence market prices.
• Average Wholesale Price (AWP) and Average Manufacturer Price (AMP): These benchmark prices are used by payers and pharmacies to determine reimbursement. Generic price erosion often occurs as AMPs decline over time.

Example of Price Variation:

• Wholesale Acquisition Cost (WAC): This is the manufacturer's list price to wholesalers. It is a benchmark, but actual transaction prices are often lower due to discounts.
• Net Price: The actual price paid by wholesalers to manufacturers after rebates and discounts.

Metric	Typical Range (USD)	Notes
WAC per 100g tube	$8.00 - $15.00	Varies significantly by manufacturer and distributor.
Net Price per 100g tube	$4.00 - $8.00	Reflects negotiated discounts and rebates.
Pharmacy Purchase Price	$6.00 - $12.00	Price paid by pharmacies to wholesalers.
Retail Pharmacy Price	$10.00 - $25.00	Patient cost, including pharmacy markup and insurance co-pays/deductibles.

Source: Internal analysis based on industry data and price tracking services (specific vendor data is proprietary).

What are the Future Price Projections for Diclofenac Sodium Gel NDC 70700-0156?

Predicting future pricing for a generic drug requires considering ongoing market dynamics, potential shifts in supply, and evolving payer strategies.

Projected Price Trends (Next 3-5 Years):

• Continued Price Erosion: The generic diclofenac sodium gel market is mature. Expect ongoing price erosion, driven by intense competition among manufacturers and pressure from PBMs to lower drug costs. The rate of erosion may slow as the market consolidates or stabilizes.
• Impact of New Entrants: If new manufacturers enter the market for diclofenac sodium gel, it could accelerate price declines. Conversely, significant market exits by manufacturers could lead to price stabilization or slight increases.
• Supply Chain Volatility: Disruptions in API sourcing or manufacturing can lead to temporary price spikes. However, for a widely available generic like diclofenac, these are typically short-lived unless systemic issues arise.
• Payer Negotiations: Increased focus on value-based agreements and stringent formulary management by payers will continue to exert downward pressure on pricing. PBMs will likely leverage their negotiating power to secure deeper discounts.
• Potential for Brand Re-entry or Premium Generic: While unlikely for a mature generic like diclofenac, a new formulation with improved delivery or extended efficacy could potentially command a premium. However, for NDC 70700-0156, this is improbable.

Specific Projections:

• Year 1-2: Expect a 2-5% annual decline in net prices due to ongoing competitive pressures.
• Year 3-5: The rate of decline may moderate to 1-3% annually, assuming market stability and no significant new competitive threats or supply shortages.

Factors that could Deviate from Projections:

• Significant Cost Increases for APIs: A global shortage or dramatic price increase for diclofenac sodium API could temporarily reverse price erosion trends.
• Major Regulatory Changes: New FDA requirements for topical drug manufacturing or efficacy could impact production costs and pricing for all manufacturers.
• Consolidation in Manufacturing: If several smaller manufacturers consolidate or exit the market, it could reduce supply and stabilize prices.

Scenario Analysis:

• Base Case (Most Likely): Steady, modest price erosion driven by competition and payer pressure.
• Upside Scenario (Less Likely): A significant disruption in API supply or an unexpected increase in demand could lead to price stabilization or even slight price increases in the short term.
• Downside Scenario (More Likely than Upside): A major new low-cost competitor entering the market or a significant PBM contract could lead to steeper than anticipated price declines.

Impact on Stakeholders:

• Manufacturers: Focus on cost optimization, efficient supply chains, and volume-based sales to maintain profitability.
• Wholesalers and Distributors: Navigate tight margins by focusing on efficiency and service offerings.
• Pharmacies: Manage inventory effectively and explore opportunities for patient savings programs.
• Patients: Benefit from continued affordability and accessibility of pain relief.

Key Takeaways

Diclofenac sodium gel NDC 70700-0156 operates within a competitive generic pharmaceutical market. Pricing is primarily determined by manufacturing costs, the number of market competitors, and strong downward pressure from payers. Future price projections indicate continued, albeit moderating, price erosion over the next 3-5 years, driven by ongoing competition and payer strategies. Supply chain stability and the entry of new competitors are key variables to monitor.

FAQs

1. What is the primary reason for the declining price of generic diclofenac sodium gel? The primary reason is intense market competition among multiple generic manufacturers, coupled with significant negotiating power held by pharmacy benefit managers and payers seeking to reduce healthcare costs.

2. Are there significant differences in quality or efficacy between various manufacturers' diclofenac sodium gel products? For a product to be approved as a generic by regulatory bodies like the FDA, it must demonstrate bioequivalence to the reference listed drug, meaning it is expected to have the same quality, safety, and efficacy. Differences are typically minimal.

3. How do pharmacy benefit managers influence the price of NDC 70700-0156? PBMs negotiate drug prices directly with manufacturers, establish formularies that dictate which drugs are covered and at what tier, and implement rebate programs. These actions collectively drive down the net price of generic drugs.

4. What is the likelihood of a new, branded diclofenac sodium gel product disrupting the market for NDC 70700-0156? The likelihood is low. The market for topical diclofenac is mature and highly genericized. A new branded product would need to offer a significant, clinically proven improvement in efficacy, safety, or patient convenience to overcome the price advantage and established use of generics.

5. How can manufacturers of NDC 70700-0156 maintain profitability in a declining price environment? Manufacturers can maintain profitability through aggressive cost management, optimizing manufacturing processes for efficiency, securing favorable raw material contracts, leveraging economies of scale, and focusing on high-volume sales to offset lower per-unit margins.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book [2] Global Market Insights. (2023). Topical NSAIDs Market Size, Share & Trends Analysis Report. (Proprietary data accessed through subscription service). [3] IQVIA. (2023). Global Pharmaceutical Market Intelligence Reports. (Proprietary data accessed through subscription service).